Virtus ETF Advisers LLC Zymeworks Inc. Transaction History

Virtus ETF Advisers LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $613 - $980	132 Added 0.74%	17,980 $111,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.7 $39,037 - $62,362	8,099 Added 83.08%	17,848 $95,000
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $3,450 - $9,763	-575 Reduced 5.57%	9,749 $64,000
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $71,803 - $138,642	4,727 Added 84.46%	10,324 $169,000
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $8,122 - $11,072	-297 Reduced 5.04%	5,597 $163,000
Q2 2021 Aug 10, 2021	BUY	$26.5 - $38.23 $1,484 - $2,140	56 Added 0.96%	5,894 $204,000
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $3,340 - $6,362	112 Added 1.96%	5,838 $184,000
Q4 2020 Feb 12, 2021	SELL	$39.12 - $54.99 $128,900 - $181,192	-3,295 Reduced 36.53%	5,726 $271,000
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $35,840 - $57,153	-1,227 Reduced 11.97%	9,021 $420,000
Q2 2020 Aug 05, 2020	BUY	$33.67 - $40.0 $56,935 - $67,640	1,691 Added 19.76%	10,248 $370,000
Q1 2020 May 14, 2020	SELL	$24.28 - $49.8 $30,398 - $62,349	-1,252 Reduced 12.76%	8,557 $304,000
Q4 2019 Feb 13, 2020	BUY	$24.84 - $45.46 $243,655 - $445,917	9,809 New	9,809 $446,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.